Skip to main content
Science
Clinical Trials
Guide to Clinical Trials
Clinical Trials in Children
Data and Results
Integrity and Transparency
Diversity
Plain Language Study Results
Expanded Access & Compassionate Use
Find a Trial
Areas of Focus
Internal Medicine
Inflammation & Immunology
Vaccines
Oncology
Diseases & Conditions
Product Pipeline
Research Sites
Products
How Drugs are Made
Branded vs. Generic
Biologics & Biosimilars
Commitment to Quality
Global Supply
Manufacturing Sites
Medicine Safety
Health Literacy
Treatment Choices
Partnering With Patients
Tips for Patients
Reporting Adverse Events
Counterfeiting
Product Safety
Product List
Product Contacts
PfizerForAll
PfizerPro for Professionals
Patient Assistance Programs
Distributors
Pfizer Distributors
Stories
Articles
Announcements
Behind the Science Features
Podcasts
eBooks
Newsroom
Press Releases
Media Asset Library
Updates and Statements
Partnering News
Media Contacts
About
People
Executives
Board Members
Scientists
Patient Stories
Colleague Stories
Responsibility
Ethics & Compliance
Responsible Business
Patient Advocacy & Engagement
Global Impact
Diversity, Equity, and Inclusion
Environmental Sustainability
Human Rights
Health & Safety
Intellectual Property
EHS Governance
Misinformation
Antimicrobial Resistance
Animals Used in Research
Stem Cell Research Policy
Programs & Policies
Grants
Political Partnership
Working with Healthcare Professionals
Prescription Value & Pricing
Privacy Principles
Ready for Cures
Transparency in Grants
Policy Positions
Investors
Investors Overview
Why Invest
Events & Presentations
Financial Reports
Investor News
Stock Information
Shareholder Services
Corporate Governance
Corporate Governance Overview
Board Committees & Charters
The Pfizer Board Policies
Corporate Governance FAQs
Contact Our Directors
Purpose
History
Careers
Partners
Research and Business Development Partnerships
Venture Investments
Business to Business
Pfizer CentreOne
Pfizer Ignite
Submit Your Opportunities
Contact Us
Careers
Investors
Search
Contact Us
Changed
Changed
How can we help you?
0
search results for
Suggestions within Pfizer.com
Header close
Header close
Home
Newsroom
Press Releases
Research Press Releases
Filter Options
Archive Date
Year
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Month
January
February
March
April
May
June
July
August
September
October
November
December
View 12
View 12
View 24
View 48
Categories
Corporate
Financial
Prescription Medicines
Research and Pipeline
Social Responsibility
Vaccines
Keywords
All Keywords
Covid-19
Finance
Investments
Leadership
Medicines
Partnerships
Research
Responsibility
Vaccines
March 2018
03.11.2018
Findings Released from Largest Real-World Data Analysis of Non-Valvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants
Research
February 2018
02.14.2018
Pfizer Receives Breakthrough Therapy Designation from FDA for PF-04965842, an oral JAK1 Inhibitor, for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
Medicines
Research
02.12.2018
U.S., EU and Japan Health Authorities Accept Regulatory Submissions for Review of Pfizer’s Third-Generation ALK Inhibitor Lorlatinib
Research
02.05.2018
Phase 3 PROSPER Trial Shows XTANDI® (enzalutamide) Significantly Reduced the Risk of Metastasis or Death by 71 Percent in Men with Non-Metastatic Castration-Resistant Prostate Cancer
Research
January 2018
01.24.2018
Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan®/MabThera®
Medicines
Research
01.19.2018
Survey of Ulcerative Colitis Patients and Gastroenterologists Indicates that Symptoms May Create a New Reality for Patients
Research
01.08.2018
Pfizer Establishes New Partnering Model for Early-Stage Academic Research
Research
01.03.2018
Sangamo and Pfizer announce collaboration for development of zinc finger protein gene therapy for ALS
Partnerships
Research
Page
13
Page
14
Page
15
Page
16
Current page
17
